Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lomustine + vincristine is a combination of two chemotherapeutic agents used primarily in the treatment of certain brain tumors, such as gliomas and medulloblastomas. Lomustine is an alkylating agent of the nitrosourea class that works by damaging DNA and RNA, thereby inhibiting cancer cell replication. Vincristine is a vinca alkaloid that disrupts microtubule formation, arresting cell division during mitosis. This combination exploits different mechanisms to target rapidly dividing tumor cells and may be used as part of multi-drug regimens or in specific protocols for central nervous system malignancies[5][8]. Both drugs are associated with significant side effects, including myelosuppression (lomustine) and neurotoxicity (vincristine)[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lomustine + vincristine.